Circulatory shock in children: An overview

Pediatrics in Review

Volumn 26, Issue 12, 2005, Pages 451-460

  McKiernan, Christine A ^a   Lieberman, Stephen A ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMRINONE; DOBUTAMINE; DOPAMINE; DROTRECOGIN; MILRINONE; NITROPRUSSIDE SODIUM; NORADRENALIN; PHENYLEPHRINE; VASOPRESSIN;

ANAPHYLACTIC SHOCK; BLEEDING; BLOOD; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CHILD; CLINICAL TRIAL; COLLOID; CRYSTALLOID; DISEASE CLASSIFICATION; FLUID THERAPY; HEART OUTPUT; HUMAN; HYPOVOLEMIC SHOCK; OXYGEN THERAPY; REVIEW; SEPSIS; SEPTIC SHOCK; SHOCK; SYMPTOMATOLOGY;

EID: 31044441849     PISSN: 01919601     EISSN: 01919601     Source Type: Journal    
DOI: 10.1542/pir.26-12-451     Document Type: Review

References (5)

1. American College of Chest Physicians/Society of Critical Care Medicine. Consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864
2. Carcillo JA, Fields AI, Task Force Committee Members. Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med. 2002;30:1365-1378
3. Brilli RJ. The role of steroids, vasopressin and activated protein C in the treatment of patients with sepsis. Presented at Current Concepts in Pediatric Critical Care Course. San Antonio, Tex; Jan 28-29, 2003
4. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709
5. Barton P, Kalil AC, Nadel S, et al. Safety, pharmacokinetics and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics. 2004;113:7-17